Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.80% | 22.44% | 17.04% | 32.99% | -5.55% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -12.69% | 111.28% | -53.37% | -51.62% | 80.84% |
| Total Other Non-Cash Items | 228.36% | -172.31% | 114.27% | -184.38% | 1,265.64% |
| Change in Net Operating Assets | -354.56% | -54.33% | 69.28% | 193.20% | -157.16% |
| Cash from Operations | -22.07% | -88.17% | 86.18% | -710.05% | 131.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -457.14% | -- | -- | -94.43% | 8,833.47% |
| Cash from Investing | -457.14% | -- | -- | -94.43% | 8,833.47% |
| Total Debt Issued | 100.00% | 110.53% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 75.00% | -- |
| Issuance of Common Stock | 2,112.87% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 188.63% | 142.11% | 531.82% | 75.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -160.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 956.86% | 108.26% | 94.44% | -220.55% | 252.28% |
